/Amgen Wins Approval for Pathbreaking Lung Cancer Drug – The Wall Street Journal

Amgen Wins Approval for Pathbreaking Lung Cancer Drug – The Wall Street Journal


A pathbreaking pill for lung cancer from Amgen Inc. was approved by the U.S. Food and Drug Administration, adding a new potential blockbuster to the biotech giant’s aging stable of drugs.

The drug, called Lumakras, was approved Friday to treat a portion of lung cancer patients with a particular genetic mutation who have already tried other therapies.

The mutation, known as KRAS, is among the most common found in cancers, but researchers struggled for so many years to find a medicine that can treat it that the mutation came to be considered “undruggable.”

The FDA’s approval, which has sped through clinical trials since the first encouraging results in 2019, is a validation for Amgen’s drug-discovery capabilities, analysts say, and a landmark in harnessing genetic discoveries to find new drugs for hard-to-treat cancers and other diseases.

Amgen is among the drugmakers that have reoriented their research efforts around insights gleaned from scientific advances in understanding the role of genetics and cell biology in disease.

Original Source